moxifloxacin has been researched along with Adnexitis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Detry, O; Haumann, A; Meunier, P; Meurisse, M; Ongaro, S | 1 |
| Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G | 1 |
| Heystek, M; Ross, JD | 1 |
| Boothby, M; Page, J; Pryor, R; Ross, JD | 1 |
| Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P | 1 |
| Broad, JM; Golden, MR; Manhart, LE | 1 |
| Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D | 1 |
| Haggerty, CL; Ness, RB | 1 |
| Aydeniz, B; Gleiter, C; Halabi, A; Kubitza, D; Stass, H; Wallwiener, D | 1 |
1 review(s) available for moxifloxacin and Adnexitis
| Article | Year |
|---|---|
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
5 trial(s) available for moxifloxacin and Adnexitis
| Article | Year |
|---|---|
Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
Topics: Adolescent; Adult; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Ofloxacin; Patient Compliance; Pelvic Inflammatory Disease; Quinolines | 2013 |
A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Double-Blind Method; Doxycycline; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Pelvic Inflammatory Disease; Quinolines; Treatment Outcome | 2009 |
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Middle Aged; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Treatment Outcome; Young Adult | 2010 |
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Ofloxacin; Pain; Pain Measurement; Pelvic Inflammatory Disease; Prospective Studies; Quinolines | 2006 |
Penetration and accumulation of moxifloxacin in uterine tissue.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Middle Aged; Moxifloxacin; Pelvic Inflammatory Disease; Prospective Studies; Quinolines; Uterus | 2008 |
4 other study(ies) available for moxifloxacin and Adnexitis
| Article | Year |
|---|---|
Acute pelvic inflammatory disease as a rare cause of acute small bowel obstruction.
Topics: Abdomen, Acute; Acute Disease; Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachomatis; Female; Humans; Intestinal Obstruction; Intestine, Small; Laparoscopy; Metronidazole; Moxifloxacin; Pelvic Inflammatory Disease; Tomography, X-Ray Computed | 2019 |
Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Endometritis; Europe; Female; Fluoroquinolones; Humans; Moxifloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Salpingitis | 2009 |
A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Middle Aged; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
Mycoplasma genitalium: should we treat and how?
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Infertility, Female; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Pelvic Inflammatory Disease; Pregnancy; Pregnancy, Ectopic; Quinolines; Treatment Outcome; Urethritis; Uterine Cervicitis | 2011 |